Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Jeffrey Neal Johnson

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

The sudden $10.6 billion acquisition of Nuvalent (NASDAQ: NUVL) by GSK (NYSE: GSK) violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.

The all-cash buyout at $124 per share represents a roughly 40% premium over recent closing levels and a 26% premium over a 30-day volume-weighted average price.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.